News

Why Specific Genetic Alterations Matter in Prostate Cancer

A given substance may be fundamental for life or may serve as a poison. All depends on the specific dose. At first glance, this somewhat paradoxical principle in medicine was first coined by the Swiss...

Circulating plasma extracellular vesicles give new insights for monitoring and managing disease progression in prostate cancer patients

The study by Albino et al. is published in Communications Biology and is available at https://doi.org/10.1038/s42003-020-01642-5. The work is a collaborative effort involving many rese...

Second generation antibody protects from SARS-CoV-2, its variant and prevents it from mutating to resist therapy

The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation ‘double antibody’ that protects from ...

New Ebolavirus treatment sees the light thanks to basic research performed in Ticino

While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treatment against another well-known virus, much les...

Congratulations to Prof. Alimonti and his Molecular Oncology team on receiving the Prostate Cancer Foundation Challenge Award

Prof. Alimonti from the Institute of Oncology Research (IOR) in Bellinzona, Switzerland and Prof. De Bono from the Institute of Cancer Research (ICR) in London, United Kingdom, just received this pres...

IOR researchers suggest that androgen-deprivation treatments for prostate cancer could protect men from COVID-19

The so-called “androgen-deprivation” treatments used in prostate cancer therapy may have a protective effect against COVID-19. A study conducted by the Istitute of Oncology Research (IOR, affiliated ...

Press review